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A number of investigators (1-7)  have reported the results of studies on the 
antibody response of human beings following the parenteral administration of 
various  preparations  containing  influenza  virus.  With  one  exception  (6) 
these earlier investigations were carried out on relatively small groups of indi- 
viduals since the difficulty of examining large numbers of sera by means of 
the neutralization test in mice was often a limiting factor.  Most workers used 
a  single variety of vaccine, although Horsfali, Lennette, and Rickard (5)  in- 
vestigated a  number of different preparations in small groups of volunteers. 
Despite the efforts which have been expended in the study of influenza virus 
vaccines in human beings, there is at present relatively little known concerning 
the factors which influence the  specific  antigenicity of the various kinds of 
vaccine which can be prepared with this agent. 
While extensive work has been done on the antibody response  of experi- 
mental animals vaccinated with various preparations of influenza virus,  the 
results obtained in such studies are not necessarily applicable to man.  Most 
human beings, unlike most experimental animals, have had at least one contact 
with influenza virus, and these previous infective experiences are probably one 
of the factors which condition their responses to vaccination with the virus in 
an unpredictable manner.  Since man is the subject whom it is desired ulti- 
mately to protect against attacks of influenza, it seems apparent that direct 
testing in human beings facilitates the evaluation of the effectiveness of various 
kinds of vaccines. 
Previous workers (1-7) have found that there was marked individual varia- 
tion in the antibody response of human beings to any one variety of influenza 
virus  vaccine.  Because of the  individual differences in response  it seemed 
necessary, in order to obtain significant data for the comparison of the specific 
antigenicity of different virus preparations in man,  to use large numbers of 
individuals in the study of each vaccine. 
With the demonstration that influenza viruses agglutinate chicken red blood 
corpuscles,  and that this capacity is specifically inhibited by immune serum 
(8), a new and relatively simple in vitro test for the determination of influenza 
antibodies became available (9).  As has been shown, the titers of influenza 
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antibodies in normal human sera, as determined by this method, very closely 
paralleled the titers obtained by means of the virus neutralization test in mice. 
This parallelism  also  obtained with  sera  from human  beings who had  been 
vaccinated recently with influenza virus.  Furthermore the test was sensitive 
to relatively small changes in antibody concentration, and the end points ob- 
tained had  a  high degree of reproducibility.  Because this method could be 
applied relatively easily to large numbers of sera it became possible to under- 
take a large-scale study of the antibody response to vaccination with influenza 
viruses in human beings. 
The experiments in the present paper were designed to explore several ques- 
tions  related  to  human  vaccination  with  influenza viruses:  (a)  How  much 
variation in individual antibody response occurs in a  large group which has 
been given a single type of vaccine, and how does the individual response vary 
with  the  prevaccination  antibody  level?  (b)  What  are  the  relative  merits 
as specific antigens of whole chick embryo vaccines prepared with and without 
the X  strain of distemper virus?  (c)  How does the antibody response vary 
with  dosage  of  influenza  virus?  (d)  How  does  active  virus  compare  with 
inactive virus as an antigen?  (e)  What is the effect of increasing the inert pro- 
tein content of the vaccine?  (f)  How rapidly do individuals lose the additional 
antibodies produced following vaccination?  (g)  How  closely does the anti- 
body response to  influenza A  virus parallel that  to influenza B  virus under 
various conditions? 
Allantoic fluid from infected chick embryos has been shown to be an excellent 
source of influenza viruses (10-12) and has been used as the source of material 
for most of these experiments.  In addition to a high virus titer, allantoic fluid 
contains relatively little non-virus protein.  Furthermore the virus present in 
such fluids can be  concentrated readily by several methods,  permitting  the 
administration  of much larger amounts of virus than heretofore. 
Methods 
Inasmuch as these studies  were designed  to compare the specific antigerdcity of 
vaccines modified in one factor only, it was essential  that the basic source material 
be the same for all preparations.  For this purpose two large pools of infected al- 
lantoic fluid were prepared, one containing the PR8 strain of influenza A virus (13) 
and the other the Lee strain of influenza 13 virus (14).  Furthermore to insure uni- 
formity the various vaccines were prepared at the same time with the exception of 
53,  54,  and  64,  which  were  handled  separately  as  will  be  explained  in  the 
text.  Usually, equal amounts of the two aUantoic fluid pools which had been treated 
similarly were combined to make the final preparation.  Chick embryo passage deriva- 
tives of the mouse-virulent PR8 and Lee strains were the only viruses used throughout 
this work, except in vaccine 64 which contained the W.S. strain (15) in addition and 
vaccine 54 which was prepared with a mixture of the PR8 strain and the X strain of 
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Preparation  of Allantoic  Fluid Pools  Used for Vacxine$.--To prepare the basic al- 
lantoic fluid pools tl-day old chick embryos were used.  The embryos were inoculated 
with 0.1 cc. of infected aflantoic fluid (diluted to 10  -8 in saline) through a small punc- 
ture in the shell over the chorioallantoic membrane.  No attempt was made to drop 
this  membrane.  After 2  days incubation  at  37°C.  blood-free allantoic fluid was 
removed under sterile conditions as described in a previous report (9).  A portion of 
the fluid from each egg was cultured in blood broth, and while the results of culture 
were being determined, the remainder of the fluids from individual eggs was stored 
frozen at  -72°C.  All contaminated fluids were discarded and the sterile fluids were 
pooled.  The combined sterile fluids were clarified by low-speed centrifugation, and 
the  sediments were  discarded.  The  pools were  then  stored at  -10°C.  until  the 
various vaccines were prepared.  Each pool was titered in mice, after it had been 
diluted serially in steps of 10  -°-s, and the 50 per cent mortality end point was deter- 
mined.  About 3,500 cc. of PR8 and 2,000 cc. of Lee fluids were prepared. 
The individual vaccines (except 53, 54, and 64) were all made from these pools on 
the  same day.  The  technique used for each preparation will be described in  the 
text.  All vaccines except 61 and 64 were frozen and dried (17) and were rehydrated 
with distilled water just before use. 
Method of Vacc/nation.--In all cases the vaccinated subjects were patients in state 
hospitals.  Their ages varied from 15 to 60 years, and they were predominantly males. 
In most instances 150 individuals were inoculated with each vaccine.  A number of 
different vaccines were given on each ward in order to rule out possible variation in 
response from one group to another.  A  blood specimen was taken from each indi- 
vidual just before vaccination and another 2 weeks following vaccination.  The sera 
were separated and stored at 4°C. until they were tested for antibody titer.  Some 
of the subjects were bled also at 6 weeks, 9 weeks, and 5 months following vaccination. 
Determination  of Antibody  Titer in Serum.--All of the human sera, both pre- and 
postvaccination specimens, were tested for their capacity to inhibit the agglutination 
of chicken red cells by the PR8  strain and the Lee strain of influenza virus.  The 
virus suspensions used for these tests were prepared in the same manner as the allantoic 
fluid pools used for vaccination.  Large quantities of each virus were prepared at one 
time.  Each pool of test virus was distributed in small amounts (2 to 25 ec.) in lus- 
teroid tubes, which were then stored at  -72°C.  until used.  Two such pools of in- 
fluenza A virus and two of influenza B  virus were necessary to complete the serum 
titrations. 
The chicken red cells used for these tests were obtained from a local slaughterhouse. 
After the cervical vessels of the chickens were severed, the blood was collected in a 
flask containing a  liter of 2 per cent sodium citrate solution.  Two liters of chicken 
blood were collected at one time.  The cells were washed three times in saline and 
after the final washing were centrifuged at 900 mP.M. for 11 minutes.  The packed 
cells were stored at 4°C. and were diluted just before use with 49 volumes of saline. 
Red cells were not used more than 1 week after being obtained. 
The sera to be tested were inactivated by heating at 56°C. for 30 minutes.  Serial 
dilutions were then made in saline, using twofold steps.  To  ~  cc. of each serum 
dilution was added ~/~ cc. of virus dilution, and to this mixture was added 1 cc. of a 
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pipetting machine which delivered the cells with such force that adequate mixing took 
place at once.  The mixtures were allowed to stand at room temperature for  1 
hours before readings were made.  This was found to give slightly sharper end points 
than readings made at 1 hour. 
The degree of red cell agglutination was read by comparing the densities of the 
supernatant fluids in the various serum dilutions with the densities of standard red 
cell suspensions.  The red cell concentrations of these standards were 1.0, 0.87, 0.75, 
0.67, 0.50, 0.37, and 0.25 per cent, and they were made up in each instance from the 
same suspension that was used for testing the sera.  The end point of a  titration 
was considered to be the tube which had a density falling between that of the 0.67 
per cent and the 0.50 per cent standard.  Frequently, however, the transition from 
complete inhibition to maximum agglutination was such that there was no tube with 
a density falling within this range.  The end point then was considered to be halfway 
between the tube of density higher than 0.67 per cent and the adjacent tube of density 
lower than 0.50 per cent.  Serum titers were expressed as the reciprocal of the dilution 
of serum in the end point tube. 
The same method of determining end points was used to standardize the virus 
preparations against which  the  sera  were  tested.  For  this measurement twofold 
dilutions of virus suspension were made in saline.  To  1 cc.  of each dilution was 
added 1 cc. of 2 per cent chicken red cells, and the end points were read after the 
mixtures had stood for 1 ~  hours.  Four times the concentration of virus capable of 
producing the end point described above was used for testing the human sera.  This 
usually resulted in the use of a final concentration  of 1:64 for the PR8 strain and 1:32 
for the Lee strain.  This amount of virus generally  produced a residual red cell density 
of 0.25 per cent or less in the supernatant of the virus control tube. 
Since slight day-to-day fluctuations  were known to occur in the degree of agglutina- 
tion obtained with a  given dilution of virus suspension, the following controls were 
set up to determine the amount of this variation.  An agglutination titration of each 
virus was set up with every series  of antibody determinations.  A more important 
control, however, was the titration of standard immune ferret sera.  With each series 
of determinations three duplicate titrations of standard sera against each virus were 
set up at the beginning, mid.dle, and end of the test.  Usually there was little or no 
difference  between the results obtained with these standards, both in the same series 
and from one series to the next.  When the controls indicated that the level of the 
test was markedly altered, the experimental results were corrected to a degree indi- 
cated by the deviation of the controls. 
A further method for eliminating errors due to unpredictable fluctuations was to 
distribute the sera obtained from individuals given a single vaccine over many series 
of determinations so that each series  usually contained some sera from individuals 
given each of the vaccines.  In this way the antibody responses produced by all the 
vaccines were submitted to an equal amount of variation in testing.  The prevaccina- 
tion and postvaccination sera from each individual were always tested in the same 
run.  Each run consisted of approximately 250 titrations, or 125 pairs of pre- and 
postvaccination sera. 
In addition to the sera from the vaccinated individuals, acute and convalescent 
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the same way.  This was done in order to establish by the same technique the levels 
of antibody obtained following infection with influenza virus.  In general, the acute 
sera were taken within the first 4 days of the illness and the convalescent sera about 
2 weeks after the onset.  All of these sera came from institutional epidemics in Ala- 
bama  in  1941,  and  had  been  tested  previously  by  the  complement  fixation  or 
neutralization  test  and  showed  at  least  a  fourfold rise in  antibody  titer  by  one 
technique or by both. 
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FIG. 1.  Antibody response against the PR8 strain at 2 weeks of 400 human beings 
who  were given form~linlv.ed chick embryo influenza vaccines 53 and 54. 
EXPERIMENTAL 
Antibody  Response of the Individual to  Vaccination.--Before  comparing  the 
average antibody responses of groups of human subjects to various vaccines, it 
was necessary to  determine first the  individual variations in response to  one 
type of preparation. 
Fig. 1 is a  spot chart of the antibody response of 400 individuals 2 weeks after the 
subcutaneous  injection  of  formalinized  preparations  of  chick  embryo  containing 
influenza A virus (vaccines 53 and 54).  The details of the preparation of these vac- 
canes will be given below.  Each dot on the chart represents the prevaccination and 
the postvaccination antibody levels of one individual against the PR8 strain of virus. 
The scale for both the pre- and the postvaccination levels is logarithmic.  The entire 
group of subjects was divided into subgroups on  the  basis of their prevacclnation 
titers, and  the geometric mean of the postvaccination levels of each subgroup was 
determined.  These mean values are represented by open circles in Fig. 1. 500  ANTIBODY  RESPONSE  TO  INFLUENZA  VACCINATION 
Since all the vaccines which were tested gave this same type of distribution 
in  antibody response,  certain  generalities  concerning  the  results  shown  in 
Fig.  1 may be of significance in the problem of vaccination against influenza 
in general.  The most obvious finding was the enormous variation in antibody 
response which occurred even among those individuals who possessed similar 
prevaccination  antibody  titers.  A  considerable  number  failed  to  show  a 
sufficient increase in antibody to be detected by this test, and the proportion of 
non-reactors was significantly greater among those individuals with high pre- 
vaccination levels than among those with low levels. 
The curved line in Fig. 1 represents the level that would have been obtained 
if an equal amount of antibody had been added to each prevaccination speci- 
men.  Since this curve closely fits the geometric means of the postvaccination 
levels found experimentally, it follows that the average actual antibody pro- 
duction as opposed to increase in titer in each of these subgroups was nearly the 
same,  regardless of the prevaccination antibody level. 
From  a  consideration of the  foregoing results  it  was  decided to  compare 
different vaccines in terms of the geometric mean antibody level obtained 2 
weeks following vaccination.  A  significant comparison between mean levels 
can be made only if the prevaccination titers are nearly the same in the groups 
under consideration.  This method is in  contrast to that  used  by Horsfall, 
Lennette, and Rickard (5) who selected individuals of low antibody titer and 
based  their conclusions mainly on the incremental increases  (times rise)  ob- 
tained  in  the  low  antibody group.  As  this  study was  based  on unselected 
groups, the incremental rises observed were lower than those found by Horsfall, 
Lennette, and Rickard.  In addition,  the method of testing which has been 
used  in  this study gives results which  show smaller differences between the 
antibody  titers  of sera  than  are  shown  either by serum  neutralization  end 
points in mice or by the calculation of neutralizing capacities.  This in no way 
invalidates  the  relationship between  the  two  tests  previously demonstrated 
(9) but merely means that  the range of titers by in vitro  measurements are 
expressed on a  compressed scale. 
In this study the geometric mean has been used for comparison of different 
vaccines because  of the  ease  of statistical  handling.  If  influenza antibody 
titers are plotted on a geometric scale, they give fairly symmetrical probability 
curves (Fig. 2), and the geometric mean of the titers is at or near the peak of 
the curve.  If the same titers are plotted on an arithmetic scale, however, the 
arithmetic mean is not at the peak of the curve, and the value of this mean is 
greatly affected by the presence or absence of a few sera of very high titer.  The 
use of the arithmetic mean would involve the employment of extremely large 
groups in order to obtain significant comparisons.  It should be emphasized 
that even when a large number of subjects are used, the variation in individual 
human response is so great that only rather large differences in the geometric 
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The Effect of the X  Strain of Distemper  Virus on the Antigenicity of Influenza 
Vaccines.--Horsfall, Lennette, and Rickard (5) reported a series of vaccination 
studies in human beings using a number of different virus preparations.  From 
their results they concluded that a  preparation of formalinized chick embryo 
virus prepared by inoculating  embryos with  a  mixture of the  PR8  strain  of 
influenza A virus and the X  strain of distemper virus had greater anfigenicity 
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FIG.  2.  Curves showing  the  distribution  of antibody titers against  influenza  A 
among a  normal population, a recently vaccinated population, and a  group of  con- 
valescent cases of influenza  A. 
than a  similar preparation made by inoculating the PR8 strain alone.  How- 
ever,  during  the past year,  further  observations in  this  laboratory have not 
borne  out  these  conclusions.  Since  it  is  now  known  that  great  individual 
variation occurs in the antibody response to vaccination, a  review of the evi- 
dence on which the comparison between these vaccines was made suggests that 
the results may have been due to errors introduced by random sampling.  It 
was decided,  therefore, to repeat these experiments on a  larger scale. 
Vaccine 53.--Eleven-day old white Leghorn embryos were inoculated with 0.05 
cc. of a 10  -8 dilution of allantoic fluid containing the PR8 strain plus 0.05 ec. of saline. 502  ANTIBODY RESPONSE TO IN~LLrENZA VACCINATION 
The inoculations were made directly into the embryo.  Mter 48 hours incubation  at 
37°C., the embryos were removed, homogenized in a Waring mixer, and diluted  to 20 
per cent concentration  with saline.  The sediment was removed by centrifugation and 
discarded.  Formalin was added to a concentration  of 1:4,000 formaldehyde.  Mter 
standing for 48 hours at 4°C. the suspension was frozen and dried.  The active embryo 
suspension gave a 50 per cent mortality fiter of 10  -~'8 in mice.  The finished vaccine 
was not infectious for mice when 0.05 cc. of a 20 per cent suspension was given intra- 
nasally.  The vaccine was rehydrated to its former volume with distilled water just 
before use, and each subject was given 1 cc. of this 20 per cent suspension subcutane- 
ously.  This was the equivalent  of 632,000 fifty per cent mouse mortality doses of 
active virus. 
Vaccine 54.--The preparation was identical  with that of vaccine 53 except for the 
inoculum used for the embryos.  The inoculum contained  0.05 cc. of a  10  -3 dilution 
of allantoic fluid containing the PR8 strain and 0.05 cc. of a 10  -3 dilution  of ground 
ferret spleen.  The spleen was obtained from a ferret that had been infected  with 
the X strain of distemper  virus.  Ferrets,  when given 1 cc. of a  10  -4 dilution  of this 
spleen suspension, came down with typical distemper.  The 50 per cent mouse mor- 
tality titer of this vaccine was 10  -5.1, and like vaccine 53, the finished preparation was 
non-infectious for mice.  Individuals who were given 1 cc. of this vaccine subcutane- 
ously received the equivalent  of 500,000 fifty per cent mouse mortality doses. 
While the technique of preparing these vaccines was not identical with that 
of Horsfall, Lennette,  and Rickard,  the differences in technique are not con- 
sidered important.  Furthermore the augmentation of antibody level produced 
by vaccines 53 and 54 was of the same order of magnitude as that observed by 
Horsfall, Lennette, Rickard, and Hirst (6) in a later and more extended series 
of vaccinations with  the  complex material. 
The antibody response to the PR8 strain produced by these two vaccines is 
shown in Table I.  It will be seen that both the mean prevaccination levels and 
the mean postvaccination levels of the two groups were nearly the same.  It 
is probable,  therefore,  that  the  addition  of the X  strain  of distemper virus 
did not significantly enhance the anfigenicity of influenza A virus. 
Although these two vaccines did not contain influenza B virus, it was decided 
to test all the sera against the Lee strain of this virus.  The results, which are 
also shown in Table I, emphasize the complete lack of antigenic relationship 
between these strains of influenza A and influenza B viruses.  They also show 
that the injection of chick embryo material, in the form of a vaccine, did not 
give rise  to  antibodies  which seriously interfered  with  the  specificity of the 
in vitro test,  even though a  chick embryo source was used for the test virus. 
Effect  of the Amount  of Virus Injected  upon  the Antibody Response.--Since 
subcutaneously administered  virus  is  not known to  multiply  in  the  human 
organism, the amount of virus given should have a pronounced effect upon the 
magnitude  of  the  antibody response  obtained,  at  least  over  a  considerable 
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determine how much the response varied when different amounts of virus were 
given. 
Vaccine 56.--This vaccine was prepared by mixing equal volumes of the PR8 and 
Lee allantoic fluid pools.  The mixture was frozen and dried and rehydrated just 
before use.  Each  individual received subcutaneously  0.1  cc.  of  the  mixed fluids 
diluted to a volume of 1 cc. with saline.  This was the equivalent of 36,200 fifty per 
cent mortality doses of the PR8 strain and 1,000 fifty per cent mortality doses of the 
Lee strain per person.  The viruses were active when injected. 
Vaccine 55.--This preparation was made in the same way as vaccine 56, but each 
individual received subcutaneously 1 cc. of the mixed fluids, or 362,000 fifty per cent 
TABLE I 
Effect of the X  Strain of Distemper  Virus on the Antigenicity of a Vaccine Containing 
Influenza A  Virus 
Vac- 
cine 
No. 
53 
54 
Preparation of  vaccine 
Formalinized  whole 
chick embryo, inocu- 
lated with PR8 only i 
Formalinized  whole  [ 
chick embryo, inocu- 
lated with PR8 and 
X strain of distem- 
per virus 
Influenza A virus (PR8 strain) 
No. 50 per 
cent 
mouse 
mortality 
doses per 
person* 
632,00C 
500,000 
: Influenza B virus (Lee strain) 
Mean 
prevac  - 
cination 
anti- 
body 
titer 
79 
77 
Mean  No. 50 
Mean  2-wk. 
prevac-  post-  per cent 
clnation  vaccma-  mouse 
anti-  tion  mortal- 
body  anti-  ity doses 
titer  body  per 
titer  person 
205  477  0 
205  486  0 
Mean 
2-wk. 
post- 
vaccina- 
tion 
anti- 
body 
titer 
84 
84 
No. 
vacci- 
nated 
196 
201 
* Before inactivation. 
mortality doses of the PR8  strain and  10,000  fifty per cent lethal doses of the Lee 
strain. 
Vaccine 57.--A large amount of PR8 allantoic fluid was centrifuged at 11,000 l~.p.x¢. 
for 2 hours, and the sediment was resuspended in a  small amount of the supernatant 
fluid.  Over 95 per cent of the virus was recovered in the sediment.  A  somewhat 
smaller amount of Lee allantoic fluid was likewise centrifuged and the sediment re- 
suspended in a  small amount  of supernatant.  These  resuspended sediments were 
combined, frozen, and dried.  The mixture was resuspended in saline at the time of 
administration and given subcutaneously in a  volume of 1 cc.  Each individual was 
given that quantity of virus originally present in 5 cc. of PR8 fluid and 2 cc. of Lee 
fluid, or 3,620,000 fifty per cent mortality doses of the PR8 strain and 40,000 fifty per 
cent mortality doses of the Lee strain.  This  represents ten  times the  amount  of 
influenza A virus and four times the amount of influenza B  virus in vaccine 55.  As 
with vaccines 55 and 56, the viruses were injected in the active state. 504  ANTIBODY  RESPONSE  TO INFLUENZA  VACCINATION 
Vaccine 64.--Although this preparation was made and given to human beings prior 
to any other vaccine reported in this paper, the sera were tested simultaneously with 
those from other vaccine groups.  The vaccine was prepared in essentially the same 
manner as vaccine 57.  Infected allantoic fluid was centrifuged at high speed and 
the sediments were pooled.  The vaccine was not dried before use but was kept at 
-72°C. until administered.  Allantoic fluid containing the W.S. strain was included, 
as well as preparations of the PR8 and Lee strains.  The amounts of virus given were 
calculated from  mouse  titrations on  the  concentrated  suspensions.  Each  subject 
received subcutaneously 190,000,000  fifty per cent mortality doses of the W.S. strain, 
24,000,000  doses of the PR8  strain, and  1,000,000  doses of the Lee strain.  These 
quantities were obtained by concentrating 24 cc. of PR8 fluid, 10 cc. of W.S., and 5 cc. 
of Lee allantoic fluid. 
TABLE I1 
Variation in the Antibody Response When Different Amounts of 
in Vaccines 
Influenza  Viruses Were Used 
Vac- 
cine 
No. 
56 
55 
57 
64 
Influenza A virus (PR8 strain) 
No. 50 per cent mouse mot- ! 
tality doses per person 
36,200 
362,000 
3,620,000 
PR8 =24,000,000 
W.S. =  190,000,000 
Influenza A 
Mean 
prevac- 
cination 
antibody 
titer 
183 
168 
163 
103 
104 
Mean 2-wk. 
postvac- 
cination 
antibody 
titer 
369 
461 
935 
1,100 
865 
Influenza B virus (Lee strain) 
No. 50 per 
cent mouse 
mortality 
doses per 
person 
1,000 
10,000 
40,000 
1,000,000 
Mean 
Mean  2-wk. 
prevac- 
cination  postvac- 
antibody  cination 
antibody 
titer  titer 
85  183 
87  276 
84  443 
57  444 
i 
90  84 
No. 
vac- 
cinated 
145 
146 
120 
43 
232 
* Cases of clinical infection included for comparison. 
Influenza A  Cases.--In this experiment were included the 232 cases of influenza A 
previously mentioned.  Each case had previously been diagnosed as influenza A  on 
the basis of a fourfold or greater rise in antibody titer, as determined by complement 
fixation or neutralization tests. 
The  results of antibody titrations on  sera obtained from  these  groups  are 
shown in Table II.  With vaccines 55, 56, and 57 the antibody response deft- 
nitely increased with each tenfold increase in the amount of virus given.  This 
is true of the response to both  the PR8  and the Lee strains.  However,  the 
degree of change of antibody titer is of a  considerably smaller magnitude than 
the differences in the amount of virus given. 
With vaccine 57,  the levels of antibody obtained were of the same order of 
magnitude as those which occurred following actual infection.  A graphic com- 
parison of these two groups is given in Fig. 2.  It will be observed that not only HIRST,  RICKARD~ W~ITMAN, AND HORSY'ALL  505 
were  the  mean  antibody levels  similar  but  the  distribution  of  titers  was 
very nearly the same.  It should be pointed out,  however, that the levels in 
the convalescent group were measured with a heterologous strain of virus, while 
the sera from group 57 were titered with a  homologous strain of virus.  This 
might tend  to  cause the  infected group to show lower titers  than  otherwise. 
On  the  other hand,  the  cases of influenza A  were arbitrarily selected on the 
basis of a  fourfold antibody rise.  If the lesser antibody responses among the 
clinical cases had been included in this group, the mean final titer would have 
been 655.  It seems unlikely that it will be possible to obtain, by vaccination, 
antibody levels which are greatly higher than those following actual infection 
by influenza viruses. 
While  vaccine 64  was given to  a  relatively small group,  and  the material 
used was not strictly comparable to that used in other experiments, the results 
are  included  as another  example of the  response obtained with  a  very large 
amount of virus.  In terms of lethal doses of both the PR8 and the Lee strains 
injected, vaccine 64 was considerably superior to vaccine 57.  In spite of this, 
the  antibody response was  of almost the  same order  of magnitude with  the 
two preparations.  This strongly suggests that further increases in the amount 
of virus injected at one time probably would not give a greatly improved anti- 
body response.  The large number of lethal doses of W.S. virus given may be 
misleading and was probably not an indication of the relative amount of anti- 
gen given. 
Relative Antigenicity of Active  Versus Inactive  Virus.--In  the following ex- 
periment a  comparison was made between the antigenicity of active influenza 
viruses (the PR8 and Lee strains) and preparations of the same viruses which 
had  been  inactivated  by  heat  or  formalin.  Since  freezing  and  drying  also 
inactivate influenza virus to some extent,  a  preparation was included  in  this 
experiment in which the vaccine was kept frozen at -- 72°C. but was not dried. 
All of the vaccines in this group were made from the allantoic fluid pools.  Each 
individual received in one subcutaneous injection  ~  ce. of the PR8 pool and  ~  cc. 
of the Lee pool.  The 50 per cent mortality end point of the PR8 pool was  10  -*.4 
and of the Lee pool was 10  -8"°.  Therefore, each individual received the equivalent 
of 362,000 fifty per cent mortality doses of influenza A vires and 10,000 fifty per cent 
mortality doses  of influenza  B  virus. 
Vaccine  55.--This  preparation  has  been  described  previously.  The  vires  was 
frozen and dried without inactivation.  Titration of the finished  vaccine, however, 
showed a  tenfold drop in mortality titer due to drying. 
Vaccine 59.--Mter equal quantities of the PR8 and Lee pools were mixed, formalin 
was added to a final concentration of 0.2 per cent formaldehyde.  The mixture stood 
at 4°C.  overnight and was frozen and dried  the following  day.  The formatinized 
miYture gave no evidence of infectivity when administered intranasally in full concen- 
tration to mice.  Each subject received subcutaneously 1 cc. of the pooled fluids. 
Vaccine 60.--Equal amounts of the PR8 and Lee pools were combined, and the 506  ANTIBODY  RESPONSE  TO  INFLUENZA  VACCINATION 
mixture was heated at 56°C. in a water bath for 15 minutes.  The heated preparation 
gave no evidence of infectivity when administered to mice intranasally in full concen- 
tration.  The vaccine was frozen and dried immediately after heating.  Each subject 
received subcutaneously 1 cc. of the mixture. 
Vaccine 61.--The preparation was the same as for vaccine 55  except that it was 
stored at  -72°C.  until administered and was not dried.  There was no significant 
loss of infectivity for mice between the time of preparation and the  time when it was 
given to h,uman beings. 
TABLE III 
Effect of Inactivation of Influenza Viruses on Antigenieity in Human Beings 
Vac- 
cine 
No. 
55 
59 
60 
61 
Preparation  of vaccine 
Active virus in allan- 
toie  fluid,  frozen 
and dried 
Virus  in  aliantoic 
fluid  inactivated 
with formalin 
Virus  in  allantoic 
fluid  inactivated 
by heating 
Active virus in allan- 
toic  fluid,  kept 
frozen,  not dried 
Influenza A  virus (PR8 strain) 
No. S0 per 
cent mouse 
mortality 
doses per 
person 
362,000 
362,000" 
362,000* 
362,000 
Influenza B  virus (Lee strain) 
Mean 
prevac- 
cinatlon 
anti- 
body 
titer 
168 
183 
163 
136 
Mean 
2-wk. 
post- 
vacclna- 
tion 
antl- 
body 
titer 
461 
429 
515 
479 
No. 50 
per cent 
mouse 
mortality 
doses per 
person 
10,000 
10,000" 
10,000" 
10,000 
Mean 
prevac- 
cination 
anti- 
body 
tlter 
87 
87 
90 
86 
Me~n 
2-wk. 
post- 
vaccina- 
tion 
anti- 
body 
titer 
276 
293 
278 
328 
No. 
vac- 
cinated 
146 
143 
144 
146 
* Before inactivation. 
The  results  of  this  experiment  are  recorded  in  Table  III.  Against  both 
influenza A  virus  and  influenza B  virus  the  mean  postvaccination antibody 
titers showed only negligible variation among the vaccines used.  Such varia- 
tion as occurred was not statistically significant.  The  same results were ob- 
tained with vaccine 55 where 90 per cent of the virus activity was lost through 
drying, yet the effect was not significantly different from vaccine 61, which had 
an unaltered mouse virulence at the time of administration.  In view of the 
fact  that  the previous experiment showed  a  significant drop in  antibody re- 
sponse when the injected antigen was reduced 90 per cent (vaccines 55 and 56), 
it seems evident that the virus which is inactivated during desiccation is not 
significantly altered as an antigen. 
Effect  of  Adding  Infected  Chick  Embryos  to  Allantoic  Fluid  Vaccines.--In 
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was decided to test preparations in which infected chick embryos were added 
to  infected  allantoic  fluid.  Since  the  chick  embryos used  for  this  purpose 
had the same virus titer as the fluids to which they were added, the effect would 
seem to be limited  to  increasing  the  proportion  of non-virus  material in  an 
allantoic fluid vaccine. 
Vaccine 62.--For this experiment chick embryos were used from the same eggs from 
which  the  allantoic fluid  pools  were  prepared.  Embryos infected  with  the  PR8 
strain were prepared separately from those containing  the Lee strain.  The chick 
embryos were ground in a Waring mixer, after the addition of enough of the allantoic 
fluid pool to make a  20 per cent chick embryo suspension.  The sediment was re- 
moved by low-speed centrifugation and equal quantities of the PR8 and Lee suspen- 
sions were mixed, frozen, and dried.  The vaccine was rehydrated just before use, 
and each subject received 1 cc. subcutaneously of the 20 per cent chick embryo sus- 
pension.  The 50 per cent mouse mortality titers of both the PR8 and the Lee sus- 
pensions were  the  same as  the  respective aUantoic  fluid  pools.  Each  individual 
received 362,000 fifty per cent mouse mortality doses of the PR8 strain and 10,000 
fifty per cent mouse mortality doses of the Lee strain. 
Vaccine 63.--This was prepared in an identical manner with vaccine 62 except that 
after mixing the two virus preparations formalin was added to a final concentration of 
0.2 per cent formaldehyde, and the mixture stood at 4°C.  overnight before freezing 
and drying.  The formalinized mixture was not infective for mice when given intra- 
nasally in full concentration. 
The results of vaccination with  these preparations are shown in Table IV. 
For  purposes  of  comparison  the  results  obtained  with  vaccine  55  prepared 
from active allantoic fluid alone are included.  A comparison of the mean post- 
vaccination  antibody  titers  shows  that  the  addition  of whole  chick embryo 
definitely enhanced  the antigenicity of both influenza A  and B  viruses, when 
the  viruses  were  in  the  active  state.  However,  when  the  preparation  was 
formalinized the antibody response was reduced to levels similar to those ob- 
tained with active allantoic fluid (vaccine 55) and with formalinized chick em- 
bryo alone (vaccines 53 and 54). 
Since the mouse mortality titers of the viruses in vaccines 55  and 62 were 
similar, it is necessary to assume either that the added chick embryo suspension 
itself  has  some  stimulatory effect or,  as  seems more  likely,  that  the  mouse 
titration does not accurately measure all of the virus in the chick embryo sus- 
pensions.  It seems possible that such suspensions contain considerable quan- 
tities of non-infective but nevertheless antigenic virus.  Why this additional 
antigenicity should disappear after formalinization is not clear. 
Since  no  preparation was  tested  to  which  uninfected  chick embryo tissue 
had  been added,  the  precise effect of inert  proteins  themselves in  influenza 
virus vaccines was not determined.  It is fairly clear, however, from a  com- 
parison of the results obtained with vaccines 53,  54,  55,  62,  and  63 that the 5O8  ANTIBODY  RESPONSE  TO  INFLUENZA  VACCINATION 
relatively low concentration of inert protein in aUantoic fluid has tittle, if any, 
beneficial effect upon the antigenicity of the virus present therein. 
Rate of Disappearance  of Antibody  Following  Vaccination.--The  groups that 
received vaccines 55  and 57  were bled 2 months following their vaccination. 
The smaller group that received vaccine 64 was bled 6 weeks and 5 months 
VLmS used  following vaccination.  These sera were tested with the same lots of  "  ' 
TABLE IV 
Effect of Added Ground Chick Embryo Tissue on the Antigenicity  of Influenza  Virus 
Vaco 
dne 
No. 
62 
63 
Preparation of vaccine 
20 per cent infected 
chick embryo di- 
luted with infected 
allantoic  fluid. 
Active virus 
Same as vaccine 62 
except preparation 
was  formallnlz~d 
Active virus in allan- 
toic fluid alone 
Influenza A virus (PR8 strain) 
Mean 
No.  50  per  Mean  2-wk. 
cent  prevac-  post- 
mouse  cinatlon  vaccina- 
mortality  antibody  tion anti- 
doses per  uw.r"  body 
person  titer 
362,000  165  658 
362,000'  166  477 
362,000  168  461 
Influenza B virus  (Lee  strain) 
No. 50 per  Mean  Mean2.wk. 
pre-  pos.t-  =ent mouse  vaccina- 
mortality  tion anti-  vaccma°  tlon suti-  doses  per  body  body 
person  titer  titer 
10,000  97  396 
10,000  90  253 
10,000  87  276 
No, 
vacci- 
nated 
144 
146 
55  146 
* Before inactivation. 
TABLE V 
Change in Mean Antibody Levels at Different Lengths of Time after Vaccination 
Antibody titer against  Antibody titer against 
Vaccine  influenza A virus (PR8 strain)  influenza B virus (Lee strain) 
NO.  Prevac-[  2-wk  [  6-wk  ]  9-wk  I  22-wk.  '  Prevac-[  /  __  cination  6-wk.  9-wk.  22-wk.  £matlon ]--  --  "  [__[  2-wk.  -- 
55  168  461  315  87  276  1  213 
57  163  935  537  57  83  443  300 
64  lo3111oo  I  54o  I  134   I  188  /  136 
for the other titrations,  and the 2-week postvaccination sera were retested at 
the same time.  The mean antibody levels are shown in Table V.  The pre- 
vaccination and the 2-week postvaccination titers are included for comparison. 
There was a rapid and considerable drop in antibody levels after the peak at 
the  2-week period.  While the loss in antibody was greater with vaccine 57 
than with vaccine 55 at 9 weeks, the former group still had a higher titer at that 
time.  Even at 22 weeks the group that had received vaccine 64 possessed anti- HII~ST~ I~ICKARD~ WHITMAN~ AND HOI~SFALL  509 
body levels considerably above their initial level.  When individual responses 
were examined, it was seen that the incremental drop in titer in all individuals 
was fairly  uniform, i.e.,  those who had responded poorly subsequently lost about 
the  same  percentage  of  their  added  antibody  as  did  those  who  had  re- 
sponded well. 
DISCUSSION 
These experiments in large groups of individuals indicate that quantitative 
rather than qualitative factors influence the specific  antigenicity of influenza 
virus  vaccines as  tested  in  human beings.  The  chief and  most  significant 
differences in antibody response were encountered when different amounts of 
virus  were  injected.  Inactivation of influenza virus,  whether  the  result  of 
formalinization, heating,  or drying,  caused but little alteration in  the  anti- 
genicity of the preparations.  Furthermore the addition of inert chick embryo 
protein,  containing inactive virus,  to  a  given vaccine did  not  significantly 
change its specific antigenicity.  However, when infected chick embryo tissue 
was added to infected allantoic fluid and the virus in the mixture was not in- 
activated, a  significantly more marked antibody response was obtained than 
with the allantoic fluid alone.  It seems possible that this unexpected result 
may have been due to the presence in the embryo tissue of a greater quantity 
of virus than was indicated by the titration of its infectiousness for mice. 
With both influenza A virus and influenza B  virus evidence was obtained 
that the average antibody response of human beings is directly related, though 
not strictly proportional, to the amount of virus given.  Although higher anti- 
body levels resulted from the administration of relatively great quantities of 
virus in concentrated preparations  (vaccine 57)  than were encountered after 
the  injection  of  unconcentrated  vaccines,  the  data  suggest  that  there  are 
definite limits to antibody response since a further increase in the quantities of 
virus  (vaccine 64)  did not increase the response appreciably. 
The present uncertain state of knowledge concerning the significance of cir- 
culating antibodies  in  resistance  to  infection by influenza viruses  makes  it 
hazardous to  attempt any prediction as to  the possible increased resistance 
which might follow the use of any of the vaccines tested in this study.  It has 
been shown that antibody levels tend to be lower in acute phase sera obtained 
from cases of influenza than they are in the general population (18, 19).  Fur- 
thermore it has been found that some reduction in the incidence of influenza A 
occurred in groups given a formalinized vaccine (6, 7, 20) which had increased 
the level of circulating antibodies.  While these observations show that there 
is some relationship between specific  circulating antibodies and resistance to 
clinical infection, there is also considerable evidence (18,  19) which indicates 
that individuals possessing the highest normal levels of circulating antibody 
are still susceptible to influenza. 510  ANTIBODY  RESPONSE  TO  IN~LIYENZA  VACCINATION 
None of the vaccines used in this study was capable of increasing the antibody 
level of all the individuals in a group to titers higher than those possessed by 
some  of  the  members  of  the  group  before  vaccination.  Consequently the 
antibody level distribution curves before and after vaccination in each group 
overlapped  by an appreciable  extent (Fig.  2).  Since the increased  antibody 
titers which followed vaccination rapidly decreased with time, there is reason 
to think that whatever degree  of increased  resistance  might result from the 
administration of a  particular influenza vaccine would  also become progres- 
sively less effective with the passage  of time. 
It should  be reemphasized  that the only satisfactory test of the possible 
efficacy of vaccines  against influenza  is  extensive  field trial under carefully 
controlled conditions.  It seems probable that the better the antibody response 
following vaccination the more likely is the development of increased resistance. 
From the results of these studies it appears that concentrated virus suspensions 
produce greater antibody responses than do other kinds of vaccines. 
SUM'~ARY 
Eleven different preparations of influenza virus were used to vaccinate large 
groups of human beings.  The antibody response to these vaccines was meas- 
ured by means of the in vitro agglutination inhibition test, and the geometric 
mean titers of sera  taken 2 weeks after vaccination were compared.  From 
these  comparisons  the  following  conclusions  were  drawn: 
1.  There was a wide individual variation in the antibody response of human 
beings  to  the same  preparation of influenza virus administrated subcutane- 
ously.  The amount of antibody produced by a group with a low prevaccina- 
tion antibody level was very nearly the same as the amount produced by groups 
that had higher initial levels. 
2.  The use of the X  strain of distemper virus in the preparation of an in- 
fluenza vaccine did not enhance the antigenicity of the influenza virus present. 
3.  Within certain limits the mean antibody response  of human beings in- 
creased as the amount of virus injected was increased.  When large amounts 
of influenza A virus were given, the antibody response was of the same order 
of magnitude as that which occurred following actual infection by this virus. 
4.  When the vaccine  was prepared from allantoic fluid, there was no sig- 
nificant difference in the antibody response of human beings given active virus, 
formalin-inactivated virus, heat-inactivated virus, or virus inactivated by the 
drying process. 
5.  Ground infected chick embryos, when diluted with infected allantoic fluid, 
gave a  greater antibody response  than aUantoic fluid alone  (when the virus 
remained active).  The  antigenicity of such  a  preparation  was  diminished 
when the virus was  inactivated by formalin. 
6.  Antibody levels 6 and 9 weeks after vaccination showed a marked drop HIRST, RICKA2d),  WHITMAN,  AND HOESI~ALL  511 
from the 2-week postvaccination levels.  In a small group the antibody levels 
at 5 months were still further reduced.  Those individuals who possessed the 
higher titers tended to lose their antibodies faster than did those at a lower level. 
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